|Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, andá…|
SD Banister, M Longworth, R Kevin, S Sachdev, M Santiago, J Stuart, ...
ACS chemical neuroscience 7 (9), 1241-1254, 2016
|Pharmacology of indole and indazole synthetic cannabinoid designer drugs ab-fubinaca, adb-fubinaca, ab-pinaca, adb-pinaca, 5f-ab-pinaca, 5f-adb-pinaca, adbica, and 5f-adbica|
SD Banister, M Moir, J Stuart, RC Kevin, KE Wood, M Longworth, ...
ACS chemical neuroscience 6 (9), 1546-1559, 2015
|Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135|
SD Banister, J Stuart, RC Kevin, A Edington, M Longworth, SM Wilkinson, ...
ACS chemical neuroscience 6 (8), 1445-1458, 2015
|Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3, 4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor|
L Ramos, C Hicks, R Kevin, A Caminer, R Narlawar, M Kassiou, ...
Neuropsychopharmacology 38 (11), 2249, 2013
|Defensive aggregation (huddling) in Rattus norvegicus toward predator odor: individual differences, social buffering effects and neural correlates|
MT Bowen, RC Kevin, M May, LG Staples, GE Hunt, IS McGregor
PLoS One 8 (7), 2013
|Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues|
SD Banister, J Stuart, T Conroy, M Longworth, M Manohar, C Beinat, ...
Forensic Toxicology 33 (2), 355-366, 2015
|In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA|
RC Kevin, TW Lefever, RW Snyder, PR Patel, TR Fennel, JL Wiley, ...
Forensic Toxicology, 2017
|Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-fluoro-CUMYL-PICA|
TF Gamage, CE Farquhar, TW Lefever, JA Marusich, RC Kevin, ...
The Journal of Pharmacology and Experimental Therapeutics, 2018
|Thermolytic degradation of synthetic cannabinoids: chemical exposures and pharmacological consequences|
BF Thomas, TW Lefever, RA Cortes, AL Kovach, AO Cox, PR Patel, ...
J Pharmacol Exp Ther, 2017
|Pharmacology of cumyl-carboxamide synthetic cannabinoid new psychoactive substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and their analogues|
M Longworth, SD Banister, R Boyd, RC Kevin, M Connor, IS McGregor, ...
ACS chemical neuroscience 8 (10), 2159-2167, 2017
|Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice|
TW Lefever, JA Marusich, BF Thomas, DG Barrus, NC Peiper, RC Kevin, ...
Substance Abuse: Research and Treatment, 2017
|Composition and use of cannabis extracts for childhood epilepsy in the Australian community|
A Suraev, N Lintzeris, J Stuart, RC Kevin, R Blackburn, E Richards, ...
Scientific reports 8 (1), 1-14, 2018
|Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA|
RC Kevin, KE Wood, J Stuart, AJ Mitchell, M Moir, SD Banister, M Kassiou, ...
Journal of Psychopharmacology, 2017
|Synthesis and pharmacology of new psychoactive substance 5F‐CUMYL‐P7AICA, a scaffold‐hopping analog of synthetic cannabinoid receptor agonists 5F‐CUMYL‐PICA and 5F‐CUMYL‐PINACA|
SD Banister, A Adams, RC Kevin, C Macdonald, M Glass, R Boyd, ...
Drug testing and analysis 11 (2), 279-291, 2019
|Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MNá…|
RC Kevin, AL Kovach, TW Lefever, TF Gamage, JL Wiley, IS McGregor, ...
Forensic toxicology 37 (1), 17-26, 2019
|Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition|
TR Arkell, N Lintzeris, RC Kevin, JG Ramaekers, R Vandrey, C Irwin, ...
Psychopharmacology 236 (9), 2713-2724, 2019
|Synthetic cannabinoid hydroxypentyl metabolites retain efficacy at human cannabinoid receptors|
TF Gamage, CE Farquhar, RJ McKinnie, RC Kevin, IS McGregor, ...
Journal of Pharmacology and Experimental Therapeutics 368 (3), 414-422, 2019
|Urinary cannabinoid levels during nabiximols (Sativex«)-medicated inpatient cannabis withdrawal|
RC Kevin, DJ Allsop, N Lintzeris, AJ Dunlop, J Booth, IS McGregor
Forensic Toxicology 35 (1), 33-44, 2017
|CUMYL-4CN-BINACA is an efficacious and potent pro-convulsant synthetic cannabinoid receptor agonist|
RC Kevin, L Anderson, IS McGregor, R Boyd, JJ Manning, M Glass, ...
Frontiers in Pharmacology, 2019
|Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN‐18|
RC Kevin, TW Lefever, RW Snyder, PR Patel, TF Gamage, TR Fennell, ...
Drug testing and analysis 10 (1), 137-147, 2018